References
- Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61(3):403-23.
- Yan T, Wang T, Tang M, Liu N. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis. Front Pharmacol. 2024;15: 1372810.
- Rajabi F, Drake LA, Senna MM, Rezaei N. Alopecia areata: a review of disease pathogenesis. Br J Dermatol. 2018;179(5):1033-48.
- Bolognia JL, Schaffer JV, Cerroni L, Callen JP, Cowen EW, Duncan KO, et al, editors. Dermatology. 5th ed. Philadelphia: Elsevier; 2024.
- Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol. 2020;29(8):703-25.
- Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2). Am J Clin Dermatol. 2023;24(3):443-51.
- Sibbald C. Alopecia areata: an updated review for 2023. J Cutan Med Surg. 2023;27(3):241-59.
- Asilian A, Mohammadian P, Shahmoradi Z. Effectiveness of oral tofacitinib treatment on patients with moderate-to-severe alopecia areata in Iran. J Cosmet Dermatol. 2024;23(3):886-90.
- Wei D, Chen Y, Shen Y, Xie B, Song X. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis. Front Immunol. 2023;14:1152513.
- Lai VWY, Bokhari L, Sinclair R. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics. Int J Dermatol. 2021; 60(9):1135-9.
- Sardana K, Bathula S, Khurana A. Which is the ideal JAK inhibitor for alopecia areata - baricitinib, tofacitinib, ritlecitinib or ifidancitinib - revisiting the immunomechanisms of the JAK pathway. Indian Dermatol Online J. 2023;14(4):465-74.
- Freitas E, Guttman-Yassky E, Torres T. Baricitinib for the treatment of alopecia areata. Drugs. 2023;83(9): 761-70.
- King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687-99.
- Zhang W, Li X, Chen B, Zhang J, Torres-Culala KMT, Zhou C. Oral tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: a retrospective study. Front Med (Lausanne). 2022;9:891434.
- King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, et al. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: results from the Phase 3 randomized, controlled trial (THRIVE-AA1). J Am Acad Dermatol. 2024;91(5):880-8.
- Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318-28.
- Zasadzińska M, owik A. JAK inhibitors in alopecia areata: current evidence and future directions. Forum Dermatologicum. 2026;12:e05026026.
- Ranjbaryan M, Weisenseel P, Karsai SA. Efficacy of tofacitinib in alopecia areata – lucky punch or robust treatment option? Int J Trichology. 2026;17(3):245-7.
Language: English
Page range: 5 - 14
Submitted on: Mar 24, 2026
Accepted on: Apr 24, 2026
Published on: Aug 10, 2026
Published by: Serbian Association of Dermatovenereologists (SAD)
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2026 Ana Segedi, Olivera Levakov, published by Serbian Association of Dermatovenereologists (SAD)
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.